PR NewswireLibertas Bio, a Formation Bio subsidiary, License of Gusacitinib, a Dual JAK/SYK Inhibitor, to SanofiYesterdayMore
Fierce BiotechSanofi signs €545M deal to explore Formation’s JAK/SYK inhibitor in new indication23 hours agoBy James WaldronMore
FirstWord PharmaSanofi licenses Formation Bio's JAK/SYK inhibitor for up to €545M19 hours agoBy Elizabeth EatonMore
Endpoints NewsFormation Bio’s up to €545M licensing deal with Sanofi; Otsuka, Harbour BioMed team up22 hours agoMore
BioSpaceIn latest AI Play, Sanofi Bets $630M+ for Formation Bio’s JAK/SYK Blocker1 hour agoBy Tristan Cesar ManalacMore
Full CoverageFull Coverage